|Hospital:||University of Chicago Medical Center|
|Patients: This Phase II study involved 20 patients with malignant mesothelioma who could not be treated by surgery or radiation alone. |
Treatment: The treatment consisted of administration of the drug edatrexate.
Toxicity: Four patients died without documentation of progressive disease. These deaths involved neutropenic sepsis, cardiac arrest, and respiratory failure from progressive mesothelioma. Grade 3-4 toxicities included hematologic, infection, nausea, emesis, muscositis, esophagitis/dysphagia, dermatologic, anorexia, malaise/fatigue, cardiac, pulmonary, renal, hepatic, and neurologic. Results: The median survival duration was 9.6 months.